ClinConnect ClinConnect Logo
Search / Trial NCT06617624

Magnetic Resonance Imaging Development for High Resolution Atrial Structural and Functional Characterization

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 25, 2024

Trial Information

Current as of June 23, 2025

Not yet recruiting

Keywords

Atrial Fibrillation Mri Acquisition Optimisation Biomarkers

ClinConnect Summary

This clinical trial is focused on improving MRI scans to better understand the left atrium, which is a part of the heart, in patients with a condition called atrial fibrillation (AF) and in healthy volunteers. The goal is to find the best way to take high-quality images that show the structure and function of the left atrium without taking too much time. This will help doctors measure important heart markers accurately.

To participate, you need to be over 18 years old and meet specific criteria. For patients with atrial fibrillation, you must be involved in another study and able to undergo an MRI. Healthy volunteers also need to be over 18 and free from significant heart problems. If you join this trial, you can expect to have an MRI scan that may involve an injection to enhance the images. It’s important to note that the trial is not yet recruiting participants, so you'll need to wait for it to begin.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • For all groups of AF patients:
  • Over 18 years of age
  • Participation to the MAESTRIA-AFNET 10 study
  • Able to undergo an injected MRI examination
  • Able to give consent
  • Affiliated to French social security system
  • Specific inclusion criteria of AF patients (same as MAESTRIA-AFNET 10) Group 1: patients with paroxysmal AF (no AF during exam) clinically defined as AF episodes less than one week Group 2: patients with persistent AF, clinically defined as AF episodes longer than one week Group 3: patients with permanent AF, with no documented sinus rhythm or possibility to restore sinus rhythm by any means
  • For healthy volunteers (Group 4):
  • Over 18 years of age (including 30 subjects \< 60 years)
  • Able to undergo an MRI examination
  • Able to give consent
  • Affiliated to French social security system
  • Exclusion Criteria:
  • For all groups
  • Deprived of liberty or under legal protection (under guardianship or curatorship)
  • Kidney disease with GFR \<30 mL / min (because of the risks linked to the injection of DOTAREM ™ and iodine)
  • Pregnant woman, breastfeeding, of childbearing age in the absence of effective contraception
  • MRI contraindication (claustrophobia, patients with metallic foreign bodies)
  • Participation to another interventional clinical trial (Jardé 1) For patients
  • Patients with a history of renal disease (renal transplant, single kidney, renal cancer)
  • Patients who have received a dose of contrast in the last 24 hours
  • Patients who had a previous allergic or anaphylactic reaction to gadolinium For volunteers
  • Subjects with known cardiovascular pathology or under cardiovascular treatment
  • Subjects with cardiovascular history
  • Subjects with cardiac rhythm or conduction disorders

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported